GH-RH Peptide Analog Design for Stability and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GH-RH analogs face challenges in maintaining high binding affinity and potency due to rapid enzymatic and chemical degradation, limiting their effectiveness in stimulating growth hormone release.
Innovation Solution
Development of synthetic GH-RH peptides with specific amino acid substitutions, such as N-Me-Tyr, D-Ala, Orn, Abu, and Nle, which enhance binding affinity and resistance to degradation, leading to increased potency and extended physiological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GH-RH analogs are designed to have high binding affinity and potency, then their effectiveness in stimulating growth hormone release is improved, but they become susceptible to rapid enzymatic and chemical degradation
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 2, 8, 12, 15, 21, 27, 29) in the GH-RH peptide sequence. Each substitution (e.g., Tyr1→N-Me-Tyr, Arg29→Agm) changes the chemical parameters of the peptide to simultaneously enhance receptor binding affinity and resist enzymatic degradation, resolving the contradiction between potency and stability
Solution Approach 2:
The patent creates composite peptide structures by combining multiple amino acid substitutions within a single GH-RH analog. The resulting peptides are composite molecules that integrate both high-affinity binding domains (e.g., modified residues at positions 1, 2, 15) and degradation-resistant domains (e.g., modified residues at positions 8, 27, 29), achieving both improved potency and enhanced stability
2Duration of action of moving object
If amino acid substitutions are made to enhance resistance to degradation, then the duration of action is extended, but the binding affinity and potency may be reduced
Solution Approach 1:
The patent uses parameter changes to simultaneously optimize both duration of action and binding affinity. By selecting specific amino acid substitutions (e.g., N-Me-Tyr at position 1 for both stability and affinity, Agm at position 29 for both resistance and potency), the patent changes the chemical parameters to achieve dual improvement rather than trade-off
Solution Approach 2:
The patent applies counterweight principles by balancing stabilizing substitutions (e.g., at positions 8, 27, 29 that resist degradation) with affinity-enhancing substitutions (e.g., at positions 1, 2, 15 that improve binding). Each stabilizing modification is counterbalanced by affinity-optimizing modifications, ensuring that extended duration does not come at the cost of reduced potency
Data Source
AI summary
The synthetic peptides have the sequence: [RrA\ A2, A6, A8, A11, A12, A15, A20, A21, A22, Nle27, A28, A29, A30]hGH-RH(1 -30)-R2 (SEQ ID NO: 1 ) wherein R1 is Ac, Tfa, or is absent, A1 is Tyr, Dat, or N-Me-Tyr, A2 is Ala, D-Ala, Abu, or D-Abu, A6 is Phe or Fpa5, A8 is Asn, Ala, Gin, Thr, or N-Me-Ala, A11 is Arg, His, or Har, A12 is Orn, or Lys(Me)2, A15 is Abu or Ala A20 is Arg, His, or Har, A21 is Orn, or Lys(Me)2, A22 is Leu, or Orn, A28 is Ser, or Asp, A29 is Arg, Har, Agm, D-Arg, or D-Har, A30 is Arg, Agm, Ada, Amc, Aha, Apa, Har, D-Arg, D-Har, Gab, Gin, D-GIn, Gin-Gab, D-Gln-Gab, or is absent, R2 is -NH2, -OH, -NHR2, -N(R2)2, or -OR2, in which R2 is any of C1-12 alkyl, C2-12 alkenyl, or C2-12 alkinyl, provided that if A29 is Agm then A30 and R2 are absent A1 is N-Me-Tyr only, and pharmaceutically acceptable salts thereof.